Richter-Helm Biologics, Gedeon Richter Plc. (“Richter”) and Helm AG’s joint venture microbial biotechnology contract development and cGMP manufacturing organization, today announced it has entered into an agreement with US based INOVIO (NASDAQ: INO) to expand its manufacturing partnership in order to support large-scale manufacturing of INOVIO’s investigational DNA vaccine for COVID-19, INO-4800, which is currently in Phase 1 clinical testing in the U.S. and and could potentially advance to Phase 2/3 efficacy trials this summer.
INOVIO has been working with Richter-Helm BioLogics since 2014. INOVIO has established commercial-scale plasmid production at Richter-Helm BioLogics for its DNA medicines platform using the manufacturing technology developed by VGXI, Inc with successful technology transfer already demonstrated in previous projects.
INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance INO-4800.